NEW YORK (TheStreet) -- Once again, biotech stocks greatly outperformed the broader market in 2014.

To give you the wide view, the  iShares Nasdaq Biotechnology ETF (IBB) - Get Report gained 34% while the SPDR S&P Biotech ETF (XBI) - Get Report , weighted more to small-cap stocks, rose 43%. The benchmark S&P 500 closed out the year with an 11% gain. 

Image placeholder title

The 10 best-performing biotech and drug stocks in 2014:

    Avanir Pharmaceuticals    405%

    OvaScience                     384%

    Agios Pharmaceuticals      384%

    Bluebird Bio                     368%

    Receptos                         323%

    TG Therapeutics               306%

    Prosensa                           302% 

    Pernix Therapeutics            273%

    Achillion Pharma             269%

    Amicus Therapeutics        254%

    Twenty-eight biotech and drugs stocks grew their market caps to $1 billion or more in 2014. Here's the top 10:

     Stock                        Market Cap        % Growth in Market Cap

      Receptos                    $3.8 billion                     613% 

      OvaScience                $1.05 billion                    574%

      Avanir Pharma            $3.3 billion                     543%

      Bluebird Bio               $2.9 billion                      476%

      Agios Pharma             $4.1 billion                     450%

      Achillion Pharma         $1.2 billion                     283%

      PTC Therapeutics        $1.5 billion                     277%

      Chimerix                    $1.4 billion                     268%

      Tetraphase                 $1.2 billion                     258%

      Horizon Pharma          $1.5 billon                      205%

      The 10 worst-performing biotech and drugs stocks in 2014:

        Nymox                         -93%

        Elbit Imaging               -92%

        Sophiris Bio                   -85%

        WaferGen BioSystems   -85%

        Rock Creek Pharmac       -84%

        Nanosphere                   -83%

        Cyclacel Pharma             -83%

        Cytori Therapeutics         -81%

        Regado BioSciences       -81%

        BioLife Solutions             -81%

        Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

        click here

        to send him an email.